Drug developer dips on failed psoriasis trial
Shares of drug developer Durect Corp. shed nearly a third of their value Thursday after the Cupertino company said its headline drug failed a mid-stage clinical trial aimed at people with itchy, scaly psoriasis.
Durect's drug, called DUR-928, has been closely watched not only because of of the psoriasis study but because it also is being tested as a treatment for alcoholic hepatitis and nonalcoholic steatohepatitis, or NASH — a fatty liver disease that is one of the hottest potential commercial…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Alcoholism | Clinical Trials | Fatty Liver Disease (FLD) | Health Management | Hepatitis | Itchiness | Liver | Liver Disease | Pharmaceuticals | Psoriasis | Study | Urology & Nephrology